# Commodore Capital LP 13F holdings Q2 2026: $1.7 billion

Commodore Capital LP reported $1.7 billion in 13F securities across 33 positions for the quarter ended June 30, 2026, in a holdings report filed August 14, 2026. Its largest holding was Relay Therapeutics Inc at $225 million, 13.4% of the reported value. Since Q1 2026 it opened 5 new positions and exited 8.

SpecStream is the live web data engine for teams and agents. It reads the SEC's Form 13F data sets each quarter, and this page is that reading, keyed on the manager's CIK and the security's CUSIP. Ask for the managers or the holdings you track, and each new 13F filing arrives in your sheet, CRM, Slack or agent as the SEC publishes it.

- Quarter: Q2 2026, the quarter ended June 30, 2026
- Reported value: $1,678,964,770
- Positions: 33
- Filed: August 14, 2026
- Report type: 13F holdings report
- CIK: 1831942
- Form 13F file number: 028-20976
- CRD number: 304370
- Business address: 444 Madison Avenue 35th Floor, New York, NY 10022
- SEC filing: [0001831942-26-000033](https://www.sec.gov/Archives/edgar/data/1831942/000183194226000033/0001831942-26-000033-index.htm)
- Investment adviser record: [Form ADV on SpecStream](https://specstream.ai/data/investment-advisers/firm/commodore-capital-304370)

## Top 25 holdings by value

The largest of 33 positions by reported value at the end of the quarter ended June 30, 2026. Put and call options are marked in the class. Change is in shares or principal against the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value | Change since Q1 2026 |
| --- | --- | --- | --- | --- |
| [Relay Therapeutics Inc](https://specstream.ai/data/institutional-holders/relay-therapeutics-inc-75943r102) | COM | 12,000,000 | $224.5 million | -5,000,000 |
| [Enliven Therapeutics Inc](https://specstream.ai/data/institutional-holders/enliven-therapeutics-inc-29337e102) | COM | 3,275,000 | $166.2 million | No change |
| [Alkermes PLC](https://specstream.ai/data/institutional-holders/alkermes-plc-g01767105) | SHS | 3,000,000 | $157.2 million | -1,200,000 |
| [Cogent Biosciences Inc](https://specstream.ai/data/institutional-holders/cogent-biosciences-inc-19240q201) | COM | 3,050,000 | $118 million | +161,993 |
| [Amylyx Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/amylyx-pharmaceuticals-inc-03237h101) | COM | 5,650,000 | $101.5 million | No change |
| [Definium Therapeutics Inc](https://specstream.ai/data/institutional-holders/definium-therapeutics-inc-24477v105) | COM SHS | 2,000,000 | $94.1 million | No change |
| [Spyre Therapeutics Inc](https://specstream.ai/data/institutional-holders/spyre-therapeutics-inc-00773j202) | COM NEW | 846,786 | $75.2 million | -1,065,594 |
| [Alto Neuroscience Inc](https://specstream.ai/data/institutional-holders/alto-neuroscience-inc-02157q109) | COM SHS | 2,723,196 | $71.9 million | No change |
| [Tango Therapeutics Inc](https://specstream.ai/data/institutional-holders/tango-therapeutics-inc-87583x109) | COM | 2,250,000 | $70.3 million | New |
| [Eyepoint Inc](https://specstream.ai/data/institutional-holders/eyepoint-inc-30233g209) | COM NEW | 4,600,000 | $65.8 million | +1,775,000 |
| [Tyra Biosciences Inc](https://specstream.ai/data/institutional-holders/tyra-biosciences-inc-90240b106) | COM | 1,875,000 | $59.9 million | -600,000 |
| [Damora Therapeutics Inc](https://specstream.ai/data/institutional-holders/damora-therapeutics-inc-36322q206) | COM NEW | 1,939,000 | $50.4 million | No change |
| [Celldex Therapeutics Inc New](https://specstream.ai/data/institutional-holders/celldex-therapeutics-inc-new-15117b202) | COM NEW | 1,350,000 | $50.2 million | -1,346,616 |
| [Pharvaris N V](https://specstream.ai/data/institutional-holders/pharvaris-n-v-n69605108) | COM | 1,425,000 | $49.3 million | -493,970 |
| [LB Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/lb-pharmaceuticals-inc-50180m108) | COM SHS | 1,500,000 | $48.7 million | No change |
| [Assembly Biosciences Inc](https://specstream.ai/data/institutional-holders/assembly-biosciences-inc-045396207) | COM NEW | 1,415,000 | $38.9 million | +415,000 |
| [Editas Medicine Inc](https://specstream.ai/data/institutional-holders/editas-medicine-inc-28106w103) | COM | 8,889,000 | $28.8 million | New |
| [Kymera Therapeutics Inc](https://specstream.ai/data/institutional-holders/kymera-therapeutics-inc-501575104) | COM | 250,000 | $28.7 million | -500,000 |
| [Perspective Therapeutics Inc](https://specstream.ai/data/institutional-holders/perspective-therapeutics-inc-46489v302) | COM NEW | 6,336,782 | $21.6 million | No change |
| [Century Therapeutics Inc](https://specstream.ai/data/institutional-holders/century-therapeutics-inc-15673t100) | COM | 8,695,652 | $21.3 million | No change |
| [Zura Bio LTD](https://specstream.ai/data/institutional-holders/zura-bio-ltd-g9ty5a101) | CLASS A ORD SHS | 3,250,000 | $19.2 million | No change |
| [Avalo Therapeutics Inc](https://specstream.ai/data/institutional-holders/avalo-therapeutics-inc-05338f306) | COM NEW | 1,018,319 | $18.8 million | +535,319 |
| [Inflarx NV](https://specstream.ai/data/institutional-holders/inflarx-nv-n44821101) | COM | 7,300,000 | $16.4 million | New |
| [An2 Therapeutics Inc](https://specstream.ai/data/institutional-holders/an2-therapeutics-inc-037326105) | COM | 2,933,680 | $14.2 million | +599,967 |
| [Nuvalent Inc](https://specstream.ai/data/institutional-holders/nuvalent-inc-670703107) | COM | 100,000 | $12.4 million | -733,600 |

## New positions in Q2 2026

5 positions not in the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| [Tango Therapeutics Inc](https://specstream.ai/data/institutional-holders/tango-therapeutics-inc-87583x109) | COM | 2,250,000 | $70.3 million |
| [Editas Medicine Inc](https://specstream.ai/data/institutional-holders/editas-medicine-inc-28106w103) | COM | 8,889,000 | $28.8 million |
| [Inflarx NV](https://specstream.ai/data/institutional-holders/inflarx-nv-n44821101) | COM | 7,300,000 | $16.4 million |
| [Research Alliance Corp III](https://specstream.ai/data/institutional-holders/research-alliance-corp-iii-g75226103) | ORD SHS CL A | 500,000 | $5.4 million |
| [Vistagen Therapeutics Inc](https://specstream.ai/data/institutional-holders/vistagen-therapeutics-inc-92840h400) | COM | 2,788,620 | $630,228 |

## Positions exited in Q2 2026

8 positions in the filing for the quarter ended March 31, 2026 and not in this one, with the shares and value reported then.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| [Erasca Inc](https://specstream.ai/data/institutional-holders/erasca-inc-29479a108) | COM | 3,175,000 | $51.4 million |
| [Xenon Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/xenon-pharmaceuticals-inc-98420n105) | COM | 825,000 | $48 million |
| [Nurix Therapeutics Inc](https://specstream.ai/data/institutional-holders/nurix-therapeutics-inc-67080m103) | COM | 2,275,000 | $35.3 million |
| [Corvus Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/corvus-pharmaceuticals-inc-221015100) | COM | 2,258,735 | $33 million |
| Soleno Therapeutics Inc | COM | 652,432 | $21.8 million |
| [Ocular Therapeutix Inc](https://specstream.ai/data/institutional-holders/ocular-therapeutix-inc-67576a100) | COM | 2,575,000 | $21.8 million |
| [Palisade Bio Inc](https://specstream.ai/data/institutional-holders/palisade-bio-inc-696389402) | COM | 7,181,062 | $12.6 million |
| [Karyopharm Therapeutics Inc](https://specstream.ai/data/institutional-holders/karyopharm-therapeutics-inc-48576u205) | COM NEW | 1,950,000 | $10.9 million |

## Also on SpecStream

- [Commodore Capital LP Form 13F filing on EDGAR](https://www.sec.gov/Archives/edgar/data/1831942/000183194226000033/0001831942-26-000033-index.htm)
- [Commodore Capital LP investment adviser record (Form ADV)](https://specstream.ai/data/investment-advisers/firm/commodore-capital-304370)
- [Largest 13F filers in New York](https://specstream.ai/data/institutional-holdings/state/new-york)
- [Largest institutional managers by 13F value](https://specstream.ai/data/institutional-holdings)
- [Most widely held securities in 13F filings](https://specstream.ai/data/institutional-holders)

Source: [the SEC's Form 13F data sets](https://www.sec.gov/data-research/sec-markets-data/form-13f-data-sets). Public data published by the US Securities and Exchange Commission (US government work). Managers report these holdings themselves in Form 13F, and the SEC does not check or guarantee them. Form 13F lists long positions in US listed equities, some options and convertible notes held at the end of the quarter, and leaves out short positions, cash, most bonds and holdings below the reporting threshold. Values are market values in US dollars as the manager filed them. A manager can ask the SEC to keep some positions confidential for a time. This page uses SEC data and is not endorsed or certified by the SEC.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in New York, New York

- [Masonry and concrete contractors in New York, New York](https://specstream.ai/data/businesses/masonry-and-concrete-contractors/new-york-new-york-united-states)
- [Day care centers in New York, New York](https://specstream.ai/data/businesses/day-care-centers/new-york-new-york-united-states)
- [Turkish restaurants in New York, New York](https://specstream.ai/data/businesses/turkish-restaurants/new-york-new-york-united-states)
- [Middle schools in New York, New York](https://specstream.ai/data/businesses/middle-schools/new-york-new-york-united-states)
- [E-commerce services in New York, New York](https://specstream.ai/data/businesses/e-commerce-services/new-york-new-york-united-states)
- [Wills, trusts and probate law firms in New York, New York](https://specstream.ai/data/businesses/wills-trusts-and-probate-law-firms/new-york-new-york-united-states)
